Somerset, NJ, Dec 14, 2021 – WhizAI, the first and only purpose-built, augmented consumer platform for the life sciences industry, raised $8 million in series A financing.
Vertical Venture Partners led this round; existing investors also participated. This latest investment brings the total amount raised by the company to over $15 million.
WhizAI is transforming how top global pharma companies use analytics to increase the top line and reduce the bottom line. They help large and mid-sized pharma:
- reduce TCO by~50% while modernizing and streamlining legacy analytics systems through intelligent automation
- empower business users in sales, commercial ops, marketing,R&D, and supply chain through contextual, actionable insights without month-long wait times and complex software that needs high-level technical skills
- improve business outcomes by identifying key opportunities, eliminating operational inefficiencies, and streamlining the analytics ecosystem
All this is possible because WhizAI is exclusive to the life sciences industry. The AI is pre-trained in the language, domain, and analytics to deliver timely, specific insights.
“We are fundamentally changing the way analytics is done in life sciences by helping our customers keep pace with large scale data, on-demand analytics, and timely insights. The future of analytics is augmented via AI to enable everyone to be insights-driven. We are delighted that our investors share this vision and support us to fulfill our mission. We will be using this investment to expand our footprint in the US and Europe and invest in all aspects of the business.” said Rohit Vashisht, co-founder and CEO, WhizAI.
David Schwab, Founder and Managing Director at Vertical Venture Partners, adds: “BI is another horizontal platform technology that needs to move to vertical-specific for customers to get the full value. Predictive and prescriptive analytics, the next phase of customer value from BI, cannot be fully realized without a vertical approach. This move from horizontal platforms to vertical solutions is the core theme of our venture fund. This vertical approach combined with a strong management team with deep BI experience makes this an ideal investment for Vertical Venture Partners.”
Through its combination of NLP, machine learning, visualization, and data scalability, WhizAI is a leap forward in business intelligence software for life sciences. The company will use the capital to grow its industry footprint by expanding its team across the globe and investing in sales and marketing so that more companies can get the fast, easy, and contextual insights necessary to compete. To learn more, please visit www.whiz.ai.
About WhizAI: WhizAI is the first and only augmented consumer platform purpose-built for the life sciences industry. It puts insights directly into the hands of business users empowering decision-makers to drive more informed and faster business decisions at a lower cost. With its deep understanding of the life sciences domain and user intent, the platform delivers insights without the delays of traditional BI dashboards. Fast, easy, and scalable,WhizAI is transforming analytics with artificial intelligence optimized for life sciences making WhizAI the trusted partner of choice at top global life sciences companies. Learn more about www.whiz.ai.
Contact: Rick Clements, Head of Marketing
People also viewed
2022 PMSA Fall Symposium
2022 PMSA FALL SYMPOSIUM October 27 – 28, 2022 Caesars Palace, Las Vegas, Nevada
Customer Centricity and Digital Experiences which are Redefining Pharma
It is no secret that the pharmaceutical industry has historically flourished from blockbuster products with substantial brand equity, favorable pricing
Awash in Data, Yet Starving for Insights? Transform Life Sciences Commercial Teams with AI-Powered Analytics
Personalized communication is something the HCPs have come to expect. To do that, pharma sales reps need to know their customers well. In order to know the customer well, they need data. Enterprise pharma companies, however, have many data resources and lots of data at their disposal. In fact, there is a data explosion. So what do you do?
Augmented Analytics is “On the Rise” on Gartner’s 2022 Hype Cycle for Life Science Commercial Operations
The Gartner® 2022 Hype Cycle™ for Life Science Commercial Operations introduces a new category, Augmented Analytics, this year. WhizAI is listed as a sample vendor in the Augmented Analytics category in this Hype Cycle. This summary report covers the following highlights.
Where Gartner Positions Natural Language Query on the Hype Cycle and What It Means for Life Sciences
Gartner® 2022 Hype Cycle™ for Natural Language Technologies (NLT) shows natural language query (NLQ) adoption is accelerating. WhizAI was recently recognized as a Sample Vendor in the Natural Language Query category in several Gartner Hype Cycles:
AI Powered Business Intelligence for Life Science Leaders: Save Time, Drive Adoption and Scale Faster
Today’s commercial teams must pinpoint top opportunities in markets across the country—or across the world—based on regulations, drug trials, market activity, competitors, insurance records, HCP preferences and affiliations, much more data than is humanly possible to manage.